Royal Bank of Canada is a leading financial services institution that provides a wide range of banking and financial solutions to individuals, businesses, and institutions. The bank offers personal and commercial banking services, wealth management, investment banking, and capital markets services. With a robust network of branch locations and digital platforms, it aims to meet the diverse needs of its clients while focusing on innovation and customer service. Royal Bank of Canada is committed to enhancing the financial well-being of its customers and leveraging its expertise to support economic growth in the communities it serves. Read More
Contineum Therapeutics (NASDAQ:CTNM) President and Chief Executive Officer Carmine Stengone said the company remains focused on advancing PIPE-791 in idiopathic pulmonary fibrosis, while recent exploratory pain data may point to additional clinical opportunities for the LPA1 receptor antagonist.
Sp
Corbus Pharmaceuticals (NASDAQ:CRBP) Chief Executive Officer Yuval Cohen said investors should expect more mature clinical updates for CRB-701 at the upcoming ASCO meeting, including the first durability and progression-free survival data for the company’s highlighted cervical and head and neck canc
RBC Bearings delivered first quarter results that surpassed Wall Street’s revenue and non-GAAP profit expectations, but the market responded negatively. Mana...
What Happened? A number of stocks fell in the afternoon session after Intuit's plunge spread across the sector and reignited the thesis that generative AI is...
What Happened? A number of stocks fell in the afternoon session after Intuit's plunge spread across the sector and reignited the thesis that generative AI is...
CG Oncology (NASDAQ:CGON) executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company’s investigational therapy for non-muscle invasive bladder cancer, and to discuss upcoming regulatory, manufacturing and commercial milestones.
The discussio
What Happened? Shares of semiconductor designer Lattice Semiconductor (NASDAQ:LSCC) jumped 9.7% in the afternoon session after CEO Ford Tamer's presentation ...
Beam Therapeutics (NASDAQ:BEAM) Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics license application for its sickle cell disease candidate possible as early as the end of this year.
Sp
What Happened? Shares of industrial conglomerate GE Aerospace (NYSE:GE) jumped 5% in the afternoon session after the company secured a U.S. Air Force contrac...
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe hypertriglyceridemia, during a fireside chat at RBC Capital Markets’ 2026 Global Healthcare Conf
Agios Pharmaceuticals (NASDAQ:AGIO) executives said the company is focused on advancing mitapivat across rare hematologic diseases, highlighting early launch traction in thalassemia and a recently submitted supplemental new drug application for sickle cell disease during a presentation at the 2026 R
ACADIA Pharmaceuticals (NASDAQ:ACAD) executives used an RBC Capital Markets investor session to outline the company’s clinical rationale for remlifanserin in Alzheimer’s disease psychosis, provide updates on commercial trends for NUPLAZID and DAYBUE, and discuss selected pipeline and business develo
Addus HomeCare (NASDAQ:ADUS) executives said a new federal moratorium on certain home health licenses should have little effect on the company’s growth plans, while highlighting continued improvement in personal care services trends and ongoing acquisition opportunities.
Speaking at an RBC healthca
While Thermo Fisher Scientific has considerably underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a highly optimistic outlook about the stock’s prospects.
Bearings manufacturer RBC Bearings (NYSE:RBC) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 18.3% year on year to $518 million. Guidanc...
